Rearrangement of anaplastic lymphoma kinase gene (ALK) is oncogenic driver which accounts for 3%–5% of patients with non‐small cell lung cancer (NSCLC).1, 2. This evidence concerns the gene ALK and non-small cell lung carcinoma.